effect of everolimus on PFS was evaluated in patients with NET of the GI tract or unknown primary site. Results: Of the 302 patients enrolled, 175 had GI NET (everolimus, 118; placebo, 57) and 36 had unknown primary (everolimus, 23; placebo, 13). In the GI subset, the median PFS by central review was 13.1 months (95% CI 9.2-17.3) in the everolimus arm versus 5.4 months (95% CI 3.6-9.3) in the placebo arm; the hazard ratio (HR) was 0.56 (95% CI 0.37-0.84). In the unknown primary patients, the median PFS was 13.6 months (95% CI 4.1-not evaluable) for everolimus versus 7.5 months (95% CI 1.9-18.5) for placebo; the HR was 0.60 (95% CI 0.24-1.51). Everolimus efficacy was also demonstrated in both midgut and non-midgut populations; a 40-46% reduction in the risk of progression or death was reported for patients in the combined GI and unknown primary subgroup. EveroliKeywords Everolimus · Neuroendocrine tumors · RADIANT-4 study · Gastrointestinal tract Abstract Purpose: The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin. Methods: Patients in the RADIANT-4 trial were randomized 2: 1 to everolimus 10 mg/day or placebo. The mus had a benefit regardless of prior somatostatin analog therapy. Conclusions: Everolimus showed a clinically meaningful PFS benefit in patients with advanced progressive nonfunctional NET of GI and unknown primary, consistent with the overall RADIANT-4 results, providing an effective new standard treatment option in this patient population and filling an unmet treatment need for these patients.
Introduction
Neuroendocrine tumors (NET) are a diverse group of tumors arising from neuroendocrine cells which are located at multiple anatomical sites in the body. Functional NET are associated with clinical symptoms due to hormonal secretion by the tumors; both nonfunctional and functional NET can present with symptoms related to the primary tumor, particularly obstruction, or symptoms from metastatic disease [1] [2] [3] [4] . More than 60% of NET originate in the gastrointestinal (GI) tract, the majority of which are nonfunctional [1, [5] [6] [7] .
Although the incidence of NET has been seen to be rising [6, 8] , limited treatment options are currently available for patients with advanced GI NET. Somatostatin analogs (SSA) are the therapy of choice for symptom control [9] [10] [11] . Recently, evidence for the efficacy of SSA in tumor control has been demonstrated with antitumor effects (improved progression-free survival [PFS]) of octreotide long-acting repeatable (LAR) first shown in the PROMID study in patients with well-differentiated metastatic midgut NET [12] . Subsequently, in the phase 3 CLARINET study, lanreotide autogel also showed an improved PFS compared to placebo in patients with advanced, proliferative index (Ki-67) <10%, nonfunctioning, enteropancreatic NET [13] . There are emerging data on the efficacy of peptide receptor radiotherapy, but access to this is not universal, and treatment options beyond SSA still remain limited.
Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor [14] , has previously demonstrated activity in patients with NET [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . In patients with advanced pancreatic NET, efficacy and safety of everolimus have been demonstrated in the large randomized, doubleblind, phase 3 RADIANT-3 study, and subsequently, everolimus was approved for clinical use [14] . In the phase 3 RADIANT-2 study, a combination of everolimus with octreotide LAR showed a 5.1-month increase in median PFS compared to placebo plus octreotide LAR in patients with advanced NET associated with carcinoid syndrome; however, this complex study narrowly missed its prespecified efficacy endpoint [16] .
In the recently conducted large phase 3 RADIANT-4 study of 302 patients with advanced, progressive, welland moderately differentiated, nonfunctional NET originating in the lung, GI tract, or an unknown primary site, everolimus improved the median PFS by 7.1 months from 3.9 to 11.0 months and reduced the risk of disease progression or death by 52% (hazard ratio [HR] 0.48; 95% confidence interval [CI] 0.35-0.67; p < 0.00001) [22] . This effect was independent of prior treatment with SSA. However, there is a considerable difference between lung NET and GI NET in terms of presentation, pathophysiology, as well as prognosis. Based on the unique biology of each NET disease type, it is important to assess each of these unique types of NET independently. This subgroup analysis of the RADIANT-4 study aimed to explore the effect of everolimus in patients with advanced, progressive, nonfunctional GI or unknown primary NET.
Patients and Methods

Study Design and Endpoints
RADIANT-4 is a large international, multicenter, randomized, double-blind, placebo-controlled, phase 3 study involving 97 centers in 25 countries which evaluated the efficacy and safety of everolimus in advanced, nonfunctional, radiologically progressive, well-and moderately differentiated GI or lung NET (NCT01524783) [22] . Patients with pancreatic NET or origins other than the GI tract and the lung were excluded. Patients with NET of unknown primary site were included according to the following definition: well-differentiated (grade [G]1 or G2) NET with primary tumor origin other than the GI tract or lung excluded by appropriate diagnostic procedures. The study was stratified for primary tumor types associated with favorable and unfavorable prognosis, prior or no prior SSA exposure, and WHO performance status.
Key eligibility criteria included patients aged ≥18 years with pathologically confirmed, advanced (unresectable or metastatic), nonfunctional, well-differentiated (G1 or G2 according to the 2010 WHO classification [13, 14] ) NET of the GI tract or lung and documented radiological disease progression within 6 months; a WHO performance status score of 0 or 1. Exclusion criteria included history of carcinoid syndrome, poorly differentiated histology, and pancreatic primary site [22] .
The primary endpoint was PFS by central radiology assessment as per modified RECIST version 1.0 [14] . Primary efficacy analyses were assessed in all randomly assigned patients on an intentionto-treat basis. The safety population included all patients who received at least 1 dose of the study drug with at least 1 post-baseline safety assessment. Adverse events (AEs) were assessed as per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The study was approved by the respective institutional review boards of the participating sites, and all patients provided written informed consent to participate.
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For the purposes of this analysis, GI origin was defined as a primary originating in the stomach, colon, rectum, appendix, cecum, ileum, duodenum, jejunum, or other origins identified by investigators as GI, mostly from the small intestine. Patients with primary tumors of unknown origin were analyzed as a separate group, although it is usually considered that the primary tumors were likely to be of small intestine origin where NET are often small and difficult to locate, particularly in the setting of metastatic disease (not an uncommon occurrence in NET). In a series of patients with metastatic disease and occult primary tumors examined surgically, primary tumors were found in the small bowel, appendix, colon, or rectum in 74.6%, and only 3.2% were found in the pancreas [27] .
The GI subgroup was further categorized into midgut and nonmidgut origin. Midgut NET included primary tumors originating in the duodenum, jejunum, ileum, cecum, appendix, and other origins identified by investigators as GI, mostly from the small intestine, while non-midgut primary tumors were defined as originating from the stomach, colon, and rectum. In addition, the efficacy was assessed in patients from the combined GI and unknown primary origin subgroup with respect to prior or no prior exposure to SSA.
Eligible patients were randomly assigned in a 2: 1 ratio to receive oral everolimus at a dose of 10 mg per day or placebo, along with best supportive care. Best supportive care included non-antitumor treatment deemed necessary by the physician, particularly antidiarrheal medication. Treatment was continued until documented radiological disease progression, start of new cancer therapy, development of an intolerable AE, or withdrawal of consent. Crossover from placebo to open-label everolimus after progression was not allowed until completion of the primary analysis.
Statistical Analysis
The median PFS was estimated using the Kaplan-Meier method [26] . The relative risk of disease progression or death comparing the everolimus and placebo arms was estimated by an unstratified Cox proportional hazards model unless otherwise stated and presented as HR. For the analyses of PFS by tumor origin, all HRs were unstratified and unadjusted for any covariates. In the primary analysis based on the overall population, patients were stratified based on prior SSA exposure as per randomization data. However, for the analysis of the prior SSA subgroup presented here, patients were classified in the prior SSA subgroups (yes vs. no) based on data from the case report forms and not on randomization data.
Results
Baseline Patient and Disease Characteristics
Of the 302 patients in the RADIANT-4 trial, 175 patients had GI NET (everolimus, 118; placebo, 57) and 36 patients had unknown primary (everolimus, 23; placebo, 13) (for the CONSORT patient flow chart, see online suppl. Figure, www.karger.com/doi/10.1159/000477585). Detailed baseline characteristics are listed in Table 1 .
Efficacy
GI and Unknown Primary Subgroups: PFS by Central Review
In the GI subgroup, a median PFS of 13.1 months (95% CI 9.2-17.3) was observed in the everolimus arm compared to 5.4 months (95% CI 3.6-9.3) in the placebo arm ( Fig. 1 ). In patients with unknown primary, the median PFS for everolimus was 13.6 months (95% CI 4.1- Values are percentages unless otherwise indicated. n.a., not applicable; G, grade. a Includes Black and Others. b For tumor grade, "low Ki-67" was defined as Ki-67 index ≤2% (G1); "high Ki-67" was defined as Ki-67 index >2% (G2); "low mitotic index" was defined as <2 mitoses/10 HPF (G1); and "high mitotic index" was defined as ≥2 mitoses/10 HPF (G2), based on a mapping between histological grade and WHO grade. c Includes peptide receptor radiotherapy. 215 not evaluable) compared to 7.5 months (95% CI 1.9-18.5) for placebo (Fig. 1) . The subgroup analyses demonstrated a consistent positive treatment effect with everolimus in all but the subgroup of patients with ileal tumors (Fig. 2) . It is likely that a beneficial effect may still be present in this more indolent population, although it is probably of a lower magnitude, which, in conjunction with other confounding factors, resulted in the observed differences in HRs between the ileal subgroup and other subgroups. To minimize the effects of small subgroups presented in Figure 2 , we retrospectively analyzed broader midgut versus non-midgut subgroups, which also has clinical validity since NET are often classified as such in clinical practice.
Midgut versus Non-Midgut Subgroups: PFS by Central Review
In the analysis of midgut (n = 115) versus non-midgut (n = 60) origin, in patients with midgut NET, everolimus showed a 6.4-month prolongation of the median PFS over placebo and a 29% reduction in the risk of progression or death based on unstratified Cox regression analysis (Fig. 3a) . In patients with non-midgut NET, everolimus showed a 6.2-month increase in the median PFS over placebo and a 73% reduction in the risk of progression or death (Fig. 3b) .
Prior-SSA versus No Prior-SSA Subgroups: PFS by Central Review Everolimus showed efficacy regardless of prior treatment with SSA as evaluated in the combined GI and unknown primary subgroup. Everolimus demonstrated an increase in median PFS of 6.7 months in patients with prior SSA exposure compared to placebo, with a 46% reduction in the risk of progression or death based on unstratified Cox regression analysis (Fig. 3c) , while in patients with no prior SSA, everolimus showed an increase in median PFS of 9.1 months compared to placebo, with a 40% reduction in the risk of progression or death based on unstratified Cox regression analysis (Fig. 3d) .
Safety
The safety set in the GI subgroup included data from 117 patients in the everolimus and 58 patients in the placebo arm. In the unknown primary subgroup, the safety set included data from 22 patients in the everolimus and 13 patients in the placebo arm. Dose reductions or temporary treatment interruptions (not adjusted for treatment duration) occurred in 79 (68%) and 13 (59%) patients receiving everolimus versus 16 (28%) and 5 (39%) patients receiving placebo in the GI and the unknown primary subgroups, respectively. Rates of on-treatment deaths (occurring during study medication or within 30 days of treatment discontinuation) were 3% (4 patients) and 5% (1 patient) in the everolimus group versus 2% (1 216 patient) and 0% in the placebo group for the GI and the unknown primary subgroups, respectively. Of these ontreatment deaths, in the GI subgroup, 2 deaths (2%, 1 case each due to respiratory failure and septic shock) in the everolimus group and 1 death (2%, due to lung infection) in the placebo group were attributed to causes other than disease progression. In the unknown primary subgroup, the one observed death was due to disease progression.
AEs were consistent with the known safety profile of everolimus and were mostly G1 or G2. Drug-related AEs occurring in at least 10% of patients with GI and unknown primary are listed in Table 2 . The most common were stomatitis, diarrhea, infections, and fatigue in both the GI and the unknown primary subgroups. Drug-related G3 or G4 AEs included stomatitis, diarrhea, anemia, and fatigue in both the GI and the unknown primary subgroups. Treatment discontinuation due to G3 or G4 AEs related to the study drug were reported in 15 (13%) patients re- were assessed by central radiology review. Duodenum (n = 10) was included in the midgut subgroup assuming that tumors were located distally. One patient with an intra-ampullary tumor (n = 1) was included in the non-midgut subgroup. The HRs were obtained with an unstratified Cox model. CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; SSA, somatostatin analogs.
ceiving everolimus and in 1 (2%) patient receiving placebo for the GI subgroup, while in the unknown primary subgroup, no G3 or G4 events led to treatment discontinuation. In the GI subgroup, everolimus-associated noninfectious pneumonitis was seen in 22 patients (19%); most were of G1 or G2 severity; G3 pneumonitis was seen in 1 patient (1%), and no G4 cases were reported. One G2 (5%) and 1 G3 (5%) noninfectious pneumonitis were reported in the unknown primary subgroup. No new safety signals, including GI toxicities, were determined as compared to the overall RADIANT-4 study population.
Discussion
Neuroendocrine neoplasms are a rare, heterogeneous population of cancers. Consequently, it has been historically difficult to perform robust, high-quality randomized clinical trials. One effective strategy has been to conduct large phase 3 trials with different subgroups of NET primaries. The RADIANT-4 study is a groundbreaking trial for nonfunctioning NET of the GI tract and the lung which demonstrates significant clinical benefit of everolimus, further supporting the previously observed benefit Values are percentages. a In the gastrointestinal subgroup, 1 patient randomized to the everolimus arm inadvertently received only placebo treatment because of a dispensation error at the site; therefore, he was included in the placebo arm; everolimus group, n = 117; placebo group, n = 58. b Includes stomatitis, aphthous stomatitis, mouth ulceration, and tongue ulceration. c Includes all infections. d Everolimus group, n = 22; placebo group, n = 13.
of everolimus in pancreatic NET [14] . However, given the heterogeneity of this patient population, a subgroup analysis is of utmost importance to understand the effect of everolimus treatment on individual NET populations. Considering that intestinal NET make up the majority of NET, examining this population specifically is of high clinical relevance and necessary to aid clinicians to best determine the benefit of everolimus treatment in individual patients. This GI subgroup analysis of the RADI-ANT-4 population is timely as recent results of the NET-TER-1 trial show a benefit of peptide receptor radiotherapy in the midgut population [28] . Without specific knowledge of the effect of everolimus therapy on the GI population (specifically midgut NET), it will be difficult for clinicians to determine the appropriate treatment for their patients.
This analysis confirmed a clinically meaningful PFS benefit in the subgroup of NET patients with GI and unknown primary treated in the everolimus arm of the RA-DIANT-4 study, of a similar degree to the overall RADI-ANT-4 cohort. In both the midgut and non-midgut subgroups, everolimus showed a marked improvement in median PFS and a reduction in the risk of progression or death compared to placebo. The ≥40% reduction in the risk of progression or death seen in patients with or without prior SSA therapy is clinically meaningful (as many patients may start with SSA) and of a similar degree to that of the previously reported overall cohort. Everolimus is an effective treatment option as a treatment for SSAnaïve patients as well as for those pretreated with SSA. In many NET patients, everolimus now represents a promising treatment option fulfilling a previously unmet need.
When considering the benefit of everolimus according to primary site, there appears to be a slightly lower degree of observable effect for patients with tumors originating in the ileum at first observation. This may partly be due to the more indolent nature of ileal NET compared to NET of other sites: the median PFS of the placebo arm was 16.7 months in the ileal NET subgroup compared to 3.9 months in the overall RADIANT-4 population. However, the HR values for the individual GI subgroups should be interpreted with caution due to possible influence of imbalances in the stratification factors as well as in other prognostic factors. In addition, variability related to the small sample size, especially due to the small number of PFS events within the majority of the subgroups, could explain part of the numerical differences between the HRs across different tumor locations. In a further analysis of the ileum subgroup, pharmacokinetic analysis showed adequate therapeutic doses available in the ileum subgroup, ruling out drug exposure as a potential cause. Better prognosis of the ileum subgroup is reflected in the rather long median PFS in the placebo arm; 16.7 months for the ileum subgroup compared to 3.9 months for the overall RADIANT-4 study population (data not shown). However, the number of events was too low in this subset of patients to draw any conclusions on the comparative efficacy of everolimus across prognostic levels. Consequently, the limited follow-up times of the study (median of 21 months) may not have allowed maturation of the data in the ileum subgroup to fully evaluate the effect of everolimus on the ileum population. The possibility, however, of a lower effect of everolimus on the ileum subgroup cannot be excluded and must be further investigated, although it seems highly unlikely given the biological background and lack of data indicating that ileum NET could have lower mTOR activation than other NET [29] [30] [31] . The activation of the mTOR pathway appears to be a consistent effect in all NET [14, 15] .
It is important to highlight that the RADIANT-4 study enrolled a population of patients with progressive NET as reflected by the 3.9-month median PFS in the placebo arm for the overall population [22] . Earlier studies in patients with NET, such as the RADIANT-2 and the CLAR-INET study, enrolled patients with less aggressive disease compared to the RADIANT-4 study population. In the RADIANT-2 study of patients with advanced NET with carcinoid syndrome, the placebo arm showed a median PFS of 11.3 months [15] . The CLARINET study enrolled gastroenteropancreatic NET patients with RECIST-based stable disease (placebo arm, 18.0 months PFS) and the primary tumor site in the GI tract being primarily midgut [12] . Comparable to the overall RADIANT-4 population, the GI and unknown primary subgroups also showed a shorter median PFS (5.4 and 7.4 months, respectively) in the placebo group indicative of the more aggressive tumor biology in these subgroups. The marked improvement in PFS upon everolimus treatment in these aggressive tumor populations demonstrates the efficacy of everolimus in patients with progressive NET where treatment options remain very limited. In particular, for the non-midgut population, everolimus showed a marked 6.2-month increase in median PFS compared to the patients who received placebo, who had a very short median PFS of only 1.9 months. In these more aggressive NET populations, everolimus appears to be a very effective new standard option.
The safety profile of everolimus in the RADIANT-4 study was consistent with previously reported studies in advanced NET, and no new safety signals were observed in the GI subgroup settings [15, 22] . The most common AEs related to everolimus treatment were stomatitis, infections, diarrhea, peripheral edema, and fatigue in both the GI and the unknown primary subgroups and were mainly G1 and G2. Treatment-related G3 or G4 AEs leading to treatment discontinuation were only seen in 13% of the patients in the GI subgroup, while no treatment discontinuation due to everolimus treatment-related G3 or G4 AEs was seen in the unknown primary subgroup. Thus, no noticeable difference in safety and adverse effects in the GI and unknown primary subgroups were observed as compared to the overall RADIANT-4 population.
As in most subgroup analyses, this analysis carries limitations as the results may have been confounded by prognostic variances in the 2 arms of the subgroups. However, results of the subgroups analyzed in this study showed consistent improvements in PFS with everolimus as was observed for the overall RADIANT-4 study.
Conclusion
In summary, in this analysis of the RADIANT-4 study, everolimus showed clinically meaningful improvements in the median PFS in nonfunctional progressive NET of GI and unknown primary compared to placebo. The safety findings were similar to previously reported studies. Everolimus thus presents an effective new standard treatment option in patients with advanced progressive nonfunctional GI NET and NET of unknown primary.
